AOD-9604
Anti-obesity fragment derived from growth hormone
Overview
AOD-9604 is a modified fragment of human growth hormone (amino acids 177-191) that retains the fat-reducing properties of HGH without its growth-promoting or diabetogenic effects. It stimulates lipolysis and inhibits lipogenesis.
Mechanism of Action
Mimics the lipolytic domain of HGH → stimulates beta-3 adrenergic receptors → enhances fat oxidation → inhibits lipogenesis without affecting blood glucose or IGF-1 levels.
Benefits
- Stimulates fat breakdown
- No effect on blood sugar
- No HGH side effects
- Supports cartilage repair
- Well-tolerated safety profile
Dosing Protocol
Half-Life
~30 minutes (rapid onset)
Duration of pharmacological activity after administration.
Side Effects
- Injection site redness
- Headache (uncommon)
- Minimal reported side effects
Stacking Recommendations
Storage & Reconstitution
Lyophilized: store at -20°C. Reconstituted: refrigerate at 2–8°C, use within 30 days.
Research Notes
Completed Phase 2 clinical trials for obesity. TGA-approved in Australia as a food supplement. Strong safety profile in human studies with moderate fat loss effects.
Medical Disclaimer
This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment recommendations. Peptide therapy should only be initiated under the supervision of a qualified healthcare provider. Individual results may vary. Always consult with your physician before starting any new therapy. Regulatory status varies by jurisdiction.